From the Journals

Engineering CAR T Cells to Resist Tumor Immune Suppression

CRISPR editing removes PGE2 receptors from therapeutic T cells, improving persistence and tumor control in preclinical models

  • By

  • March 9, 2026

  • 2 min

Share

  • 1

    CAR T cells are now being engineered to evade tumor-imposed suppression.

  • 2

    EP2 and EP4 receptors were targeted using CRISPR–Cas

  • 3

    Enhanced CAR T cells showed improved persistence in tumor environments.

  • 4

    Improved outcomes observed in pancreatic cancer, melanoma, and more.

  • 5

    PGE2 is a key mediator in tumor immunosuppression.

  • 6

    Future clinical studies are planned to evaluate this new approach.

  • 7

    Research may initially focus on lymphomas before solid tumors.

Original Source(s)

Engineering CAR T Cells to Resist Tumor Immune Suppression

CRISPR editing removes PGE2 receptors from therapeutic T cells, improving persistence and tumor control in preclinical models

  • March 9, 2026

  • 2 min

Related Content

Accelerating Structure-based Drug Design for Complex Membrane Proteins

Nuclera and leadXpro partnership will deliver AI-guided end-to-end workflow to access challenging membrane protein targets

  • March 9, 2026

  • 3 min
Are AI Models Cheating in Biomarker Predictions?

Study finds image-based predictions often reflect confounding factors rather than true molecular signals

  • March 6, 2026

  • 3 min
The Strategic Role of CRA AI Agents in Clinical Research

Using agentic AI to reduce clinical trial inefficiency